KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Shares OutstandingShares Outstanding (Weighted Average)
Others
Ratios

AbCellera Biologics (ABCL) Research & Development (2020 - 2023)

AbCellera Biologics' Research & Development history spans 4 years, with the latest figure at $48.6 million for Q4 2023.

  • For the quarter ending Q4 2023, Research & Development rose 72.14% year-over-year to $48.6 million, compared with a TTM value of $175.7 million through Dec 2023, up 62.83%, and an annual FY2024 reading of $167.3 million, down 4.78% over the prior year.
  • Research & Development for Q4 2023 was $48.6 million at AbCellera Biologics, up from $37.9 million in the prior quarter.
  • The five-year high for Research & Development was $52.6 million in Q1 2023, with the low at $4.1 million in Q1 2020.
  • Average Research & Development over 4 years is $23.4 million, with a median of $21.9 million recorded in 2021.
  • Year-over-year, Research & Development soared 199.95% in 2021 and then soared 36.68% in 2023.
  • Tracing ABCL's Research & Development over 4 years: stood at $8.6 million in 2020, then surged by 99.27% to $17.2 million in 2021, then surged by 64.13% to $28.2 million in 2022, then skyrocketed by 72.14% to $48.6 million in 2023.
  • Per Business Quant, the three most recent readings for ABCL's Research & Development are $48.6 million (Q4 2023), $37.9 million (Q3 2023), and $36.5 million (Q2 2023).